Zhi Tong Cai Jing·2026-01-05 09:04Core Viewpoint - The AI medical market has significant potential, and iFlytek Medical Technology (02506) possesses a self-developed foundational model, continuously enhancing its performance ceiling. The company is the primary beneficiary of policy dividends and national projects in the AI medical sector, warranting ongoing attention [1]. Group 1: Shareholder Actions - Major shareholders, including the parent company iFlytek (002230) and key investors, voluntarily extended the lock-up period for their shares by one year until December 29, 2026, committing not to reduce their holdings during this period. As of the announcement date, these shareholders collectively held 52,758,395 H-shares, accounting for 68.25% of the total H-share capital and 72.86% of the total share capital [1][2]. Group 2: Technology and Product Development - In March 2025, the company launched the "iFlytek Spark Medical Model X1," the only medical deep reasoning model fully trained using domestically produced computing power. In real-world testing, its general auxiliary diagnosis accuracy reached 94.0%. By July 2025, the model's capabilities were upgraded, with the general auxiliary diagnosis accuracy improving to 95.0%, and other performance metrics also showing significant enhancements [3]. - The company’s deep reliance on its self-developed "Spark" model, based entirely on domestic computing power, provides two core advantages: strong market entry barriers due to data security and autonomy, especially in government and large public hospitals, and a feedback loop for continuous improvement of the model through accumulated data and application experience [3]. Group 3: Market and Policy Environment - The AI+medical sector is a clear direction for policy growth, with the company positioned to benefit significantly from this trend. Amid tightening fiscal and healthcare cost controls, traditional medical IT investments face pressure, while AI is recognized as a means to enhance grassroots diagnosis and optimize resource allocation, supported by various national policies [4]. - Revenue forecasts for the company are projected at 930 million yuan, 1.21 billion yuan, and 1.58 billion yuan for 2025-2027, with corresponding price-to-sales ratios of 8.5x, 6.5x, and 5x [4].